Geron (GERN) Total Non-Current Liabilities (2012 - 2026)
Geron (GERN) posted Total Non-Current Liabilities of $194.6 million for Q1 2026, down 16.3% sequentially from $232.5 million in Q4 2025, and down 56.95% YoY from $452.1 million in Q1 2025.
Geron (GERN) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Geron has reported Total Non-Current Liabilities for 6 years, with the latest figure at $194.6 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 56.95% year-over-year to $194.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $194.6 million (down 56.95% YoY) and the FY2025 annual result came in at $232.5 million, up 11.24% from the prior year.
- Total Non-Current Liabilities fell to $194.6 million in Q1 2026 per GERN's latest filing, from $232.5 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $457.3 million in Q3 2025 and troughed at $194.6 million in Q1 2026.
- A 3-year average of $331.7 million and a median of $338.6 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities grew 11.24% in 2025, then tumbled 56.95% in 2026.
- Over 3 years, Total Non-Current Liabilities stood at $209.0 million in 2024, then grew by 11.24% to $232.5 million in 2025, then slipped by 16.3% to $194.6 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $194.6 million, $232.5 million, and $457.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 191.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 191.46 Mn |
| Mar 31, 2026 | 194.63 Mn |
| Dec 31, 2025 | 232.53 Mn |
| Sep 30, 2025 | 457.34 Mn |
| Jun 30, 2025 | 444.67 Mn |
| Mar 31, 2025 | 452.07 Mn |
| Dec 31, 2024 | 209.04 Mn |
| Dec 31, 2014 | 172.50 Mn |
| Sep 30, 2014 | 144.25 Mn |
| Jun 30, 2014 | 149.05 Mn |
| Mar 31, 2014 | 155.27 Mn |
| Dec 31, 2013 | 66.98 Mn |
| Sep 30, 2013 | 68.46 Mn |
| Jun 30, 2013 | 73.36 Mn |
| Mar 31, 2013 | 82.83 Mn |
| Dec 31, 2012 | 99.75 Mn |